Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


Women's Wellness Device Developer Posts In-Line Quarter, Catalysts Looming
Research Report

Share on Stocktwits


A review of this Colorado company's first numbers of the year was provided in a Ladenburg Thalmann report.

In a May 13 research note, Ladenburg Thalmann analyst Jeffrey Cohen reported that Viveve Medical Inc.'s (VIVE:NASDAQ) Q1/19 "reads fine."

Q1/19 revenue, net loss and loss per share were $3 million, $10 million and $0.22 versus Ladenburg's projections of $3.3 million, $8.6 million and $0.27, respectively. During the quarter, Viveve sold 43 systems and 2,300 disposable treatment tips, the latter still accounting for most of the revenue. Revenue from tips sales grew to 19% from 6% of total revenue in two years' time.

Viveve developed an internal care team whose members will be the main point of contact for its customers. The company also launched programs in which they provide physicians with best practices and peer experiences globally.

Operating expenses during Q1/19 were $9.8 million, higher than Ladenburg's estimated $9.3 million, mostly due to higher-than-expected selling, general and administrative costs. Those came in at $6.6 million, above the financial services company's $6.1 million forecast. On the other hand, research and development expenses were less than anticipated, at $2.5 million versus $3.2 million.

Gross margins for Q1/19 were less than Ladenburg predicted, at 36% compared to 45%. Cohen commented that Viveve likely will increase revenue through sales of its system's 2.0 version and from partners manufacturing the various components at a lower cost.

Upcoming catalysts, Cohen noted, are a full data readout in July 2019 from the LIBERATE International trial, Viveve's ex-U.S. stress urinary incontinence study. Q3/19 could potentially bring U.S. Food and Drug Administration clearance of Viveve's system domestically.

Ladenburg has a Buy rating and a price target of $2.50 per share on Viveve, whose current share price is around $0.46.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Viveve Medical, a company mentioned in this article.

Disclosures from Ladenburg Thalmann, Viveve Medical Inc., May 13, 2019

ANALYST CERTIFICATION: I, Jeffrey S. Cohen, attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report, provided, however, that:

The research analyst primarily responsible for the preparation of this research report has or will receive compensation based upon various factors, including the volume of trading at the firm in the subject security, as well as the firm’s total revenues, a portion of which is generated by investment banking activities.


Ladenburg Thalmann & Co. Inc. makes a market in Viveve Medical, Inc.

Ladenburg Thalmann & Co. Inc. has managed or co-managed a public offering for Viveve Medical, Inc. within the past 12 months.

Ladenburg Thalmann & Co. Inc received compensation for investment banking services from Viveve Medical, Inc. within the past 12 months.

Ladenburg Thalmann & Co. Inc had an investment banking relationship with Viveve Medical, Inc. within the last 12 months.

Want to read more about Medical Devices investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe